KMDA (KMDA) Stock Price & Analysis
KMDA (KMDA) rose 1.44% to USD 7.06 as of July 25, 2026 at 08:04 UTC, according to Nexqual real-time market data.
KMDA last closed at USD 6.96; the session ranged USD 7–7.13 on volume of 17,803 shares. Market capitalization is $407.32M, with a 52-week range of USD 6.5–9.35 (NMS). Source: Nexqual, July 25, 2026 at 08:04 UTC.
Key Statistics (as of July 25, 2026 at 08:04 UTC)
| Price | USD 7.06 |
|---|---|
| Change | ▲ 1.44% (up) |
| Previous Close | USD 6.96 |
| Open | USD 7.01 |
| Day Range | USD 7 – 7.13 |
| 52-Week Range | USD 6.5 – 9.35 |
| Volume | 17,803 shares |
| Market Cap | $407.32M |
| Exchange | NMS |
Technical Analysis (KMDA)
Nexqual's technical model rates KMDA "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 08:04 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.16 (neutral) |
| vs SMA50 | Below (USD 7.41) |
| MACD | -0.11 (negative) |
Analyst Ratings (KMDA)
Wall Street analysts rate KMDA "Strong Buy" based on 4 analysts, with a mean price target of USD 13 (range USD 11–15), per Nexqual as of July 25, 2026 at 08:04 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 13 |
| High Target | USD 15 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (KMDA)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD 0.11 |
| Revenue Estimate | $149.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est 0.12 ▼ miss |
| 2025-12-31 | USD 0.06 vs est 0.08 ▼ miss |
| 2025-09-30 | USD 0.09 vs est 0.09 ▼ miss |
| 2025-06-30 | USD 0.13 vs est 0.09 ▲ beat |
Source: Nexqual, July 25, 2026 at 08:04 UTC.
Financials & Fundamentals (KMDA)
| Total Revenue | $181.68M |
|---|---|
| Revenue Growth (YoY) | +2.80% |
| Gross Margin | +41.16% |
| Operating Margin | +15.37% |
| Profit Margin | +11.21% |
| ROE | +7.97% |
| Debt / Equity | 4.49 |
| Current Ratio | 3.33 |
| Total Cash | $73.15M |
| Total Debt | $11.64M |
| Free Cash Flow | $11.08M |
Source: Nexqual, July 25, 2026 at 08:04 UTC.
Financial Health Score (KMDA)
Nexqual rates KMDA's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:04 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 15% |
| Balance Sheet | Strong — $73M cash vs $12M debt, net cash position |
| Cash Flow | Mixed — FCF $11M, slim 2.0% margin |
| Efficiency | Mixed — ROE 8%, ROA 4.2% |
Ownership (KMDA)
| Insider Ownership | +7.20% |
|---|---|
| Institutional Ownership | +48.51% |
| Shares Outstanding | 57.69M |
| Float | 31.45M |
| Short % of Float | +0.42% |
Source: Nexqual, July 25, 2026 at 08:04 UTC.
Leadership (KMDA)
KMDA is led by Amir London (age 56), Chief Executive Officer, per Nexqual as of July 25, 2026 at 08:04 UTC.
| Chief Executive Officer | Amir London (age 56) |
|---|---|
| Chief Financial Officer | Chaime Orlev (age 55) |
| Chief Operating Officer | Eran Nir (age 52) |
| Vice President of US Commercial Operations | Jon R. Knight (age 59) |
| Vice President of Business Development & Strategic Programs | Boris Gorelik (age 43) |
Major Backers & Investors (KMDA)
Notable institutional backers of KMDA include Phoenix Financial Ltd., Renaissance Technologies, Wells Fargo & Company, according to Nexqual as of July 25, 2026 at 08:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Phoenix Financial Ltd. | 2.87% |
| Renaissance Technologies | 1.32% |
| Wells Fargo & Company | 1.04% |
| ARK Invest | 0.93% |
| Acadian Asset Management. LLC | 0.64% |
| DFA INVESTMENT TRUST CO-The Continental Small Company Series | 0.57% |
| Two Sigma Investments, LP | 0.34% |
| Envestnet Asset Management Inc. | 0.29% |
Source: Nexqual, July 25, 2026 at 08:04 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RDHL | Redhill Biopharma Ltd. | USD 0.63 | ▼ 7.55% |
| MDWD | MediWound Ltd. | USD 14.23 | ▼ 1.32% |
| EVGN | Evogene Ltd. | USD 0.54 | ▲ 0.46% |
| ENLV | Enlivex Ltd. | USD 4.2 | ▼ 8.4% |
| URGN | UroGen Pharma Ltd. | USD 40.97 | ▼ 2.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:04 UTC. This page is informational and not investment advice.